BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events


BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events

Item 8.01 Other Events.

On April21, 2017, BeiGene,Ltd. (the Company) issued a press
release announcing the dosing of the first patient in a pivotal
clinical trial of BGB-A317, an investigational humanized
monoclonal antibody, designed to investigate the efficacy and
safety of BGB-A317 in Chinese patients with relapsed or
refractory classical Hodgkin lymphoma.The full text of the
Companys press release is filed as Exhibit99.1 to this Current
Report on Form8-K and is incorporated herein by reference.

Item9.01 Financial Statements and

(d) Exhibits.




Press Release issued on April21, 2017


BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

BEIGENE, LTD. (NASDAQ:BGNE) Recent Trading Information

BEIGENE, LTD. (NASDAQ:BGNE) closed its last trading session 00.00 at 36.98 with 70,638 shares trading hands.

An ad to help with our costs